Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPersimmon Regulatory News (PSN)

Share Price Information for Persimmon (PSN)

Share Price is delayed by 15 minutes
Get Live Data
1,078.50    26.00 (2.47%)
Bid:
1,071.00
Ask:
1,072.00
Spread: 1.00 (0.093%)
Market Cap: £3.46b
PSN Live PriceLast checked at - London Stock Exchange

Intraday Persimmon Share Chart

Trading Statement

7 Jul 2009 07:00

RNS Number : 2152V
Persimmon PLC
07 July 2009
 



TRADING UPDATE

TUESDAY 7 JULY 2009

Persimmon plc announces the following trading update ahead of its Interim Results to 30 June 2009, which will be released on Tuesday 25 August 2009.

During the six months ended 30 June 2009 we legally completed 4,006 homes with total sales revenue of c. £625 million (June 2008: £998 million). Borrowings at 30 June 2009 were lower than originally anticipated at c. £495 million (June 2008: £906 million)representing a gearing level of c. 32%. This places the business in a strong position to deliver the £450 million year end borrowings previously indicated.

At 23 April 2009 we stated that sales for the first 16 weeks of the year were ahead of our expectations. Since then sales volumes have consistently been ahead of the same period of 2008. More recently, both volume and revenues have shown increasing improvement on the comparative weeks of the previous year.

Forward sales revenue into the second half of 2009 is c. £700 million. This compares with forward sales revenue of c. £458 million at 1 January 2009 and c. £650 million at the same time last year.

We expect this improving trend to continue against the weak conditions experienced throughout the second half of 2008. House prices have continued to decline throughout the six month period with an underlying reduction of c. 4% for the Group. The rate of decline has however reduced and our recent experience is that prices are now stabilising in some locations.

Further indications of an improved housing market are evidenced by the historically low level of cancellations of c. 16% we are currently experiencing and the significant reduction in our part exchange stock to c. £17 million (June 2008: £120 million).

Whilst we continue to monitor work in progress levels very closely, we have invested where we can realise good sales and cash flow. During the first half of this year we opened 45 new developments and plan to commence work on a further c. 50 sites during the second half. Currently we have c. 390 operating sales outlets (January 2009: c. 420) (June 2008: c. 460).

Our landbank consists of c. 64,500 plots (June 2008: 76,159 plots). This represents a very healthy c. 7 years' supply at current rates of sale. Given the good geographic spread and focus on more traditional house types within our landbank, currently we do not need to acquire more land to sustain our business. However, we are identifying a small number of opportunities where we are able to agree terms to purchase new land on favourable terms. Despite this we have not experienced any noticeable increase in the availability of good quality land at attractive prices.

At the end of 2008 we carried out a prudent review of our landbank in the light of market conditions which we anticipated would lead to further market weakness. Unless there is a substantial change in current market conditions, we do not expect any requirement for further provisions. 

We are encouraged by the improvement in sales rates when compared to last year, but will remain cautious until mortgage availability improves further and employment prospects stabilise. In the meantime, we will continue to focus on cash generation and the reduction of debt levels in our business to ensure that Persimmon remains in a strong position.

Mike Farley and Mike Killoran will host a meeting with analysts at 9.00am at Merrill Lynch, 2 King Edward StreetLondon EC1A 1HQ.

Analysts wishing to participate remotely may dial 01452 569 103 followed by the conference ID 15224487.

For further information, please contact:

Persimmon plc

Mike Farley, Group Chief Executive

Mike Killoran, Group Finance Director

On 7 July 2009:  +44 (0) 207 153 1533

Thereafter: +44 (0) 1904 642 199 

M: Communications

Edward Orlebar:  +44 (0) 207 153 1523 / +44 (0) 7738 724 630

Charlotte McMullen:  +44 (0) 207 153 1549 / +44 (0) 7921 881 800

Marylene Guernier:  +44 (0) 207 153 1269 / +44 (0) 7776 303 788


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTRFMFTMMMMBFL
Date   Source Headline
1st May 20257:00 amRNSAGM Trading Statement
25th Apr 202510:54 amRNSHolding(s) in Company
25th Apr 20259:24 amRNSHolding(s) in Company
11th Apr 20254:22 pmRNSHolding(s) in Company
3rd Apr 202510:15 amRNSHolding(s) in Company
2nd Apr 202512:22 pmRNSHolding(s) in Company
1st Apr 202512:03 pmRNSTotal Voting Rights
31st Mar 20253:14 pmRNSDirector/PDMR Shareholding
27th Mar 202510:08 amRNSHolding(s) in Company
25th Mar 20253:14 pmRNSDirector/PDMR Shareholding
24th Mar 20253:35 pmRNSAnnual Report 2024 and Notice of AGM 2025
24th Mar 20252:24 pmRNSHolding(s) in Company
11th Mar 20257:00 amRNSFull Year Results
6th Mar 20252:06 pmRNSHolding(s) in Company
3rd Mar 20253:35 pmRNSHolding(s) in Company
3rd Feb 202512:26 pmRNSTotal Voting Rights
14th Jan 20257:00 amRNS2024 Trading Statement
2nd Jan 20251:00 pmRNSTotal Voting Rights
10th Dec 20243:47 pmRNSDirectorate Change
2nd Dec 20242:11 pmRNSBlock listing Interim Review
2nd Dec 202412:00 pmRNSTotal Voting Rights
6th Nov 20247:00 amRNSQ3 Trading Statement
5th Nov 20241:31 pmRNSHolding(s) in Company
1st Nov 20243:59 pmRNSTotal Voting Rights
1st Oct 20241:19 pmRNSTotal Voting Rights
24th Sep 202412:25 pmRNSDirector/PDMR Shareholding
2nd Sep 20241:44 pmRNSTotal Voting Rights
8th Aug 20247:00 amRNSHalf Year Results
1st Aug 20242:32 pmRNSTotal Voting Rights
23rd Jul 202410:28 amRNSDirectorate Change
1st Jul 20241:10 pmRNSTotal Voting Rights
19th Jun 20242:48 pmRNSDirector/PDMR Shareholding
3rd Jun 202412:33 pmRNSBlock listing Interim Review
3rd Jun 202411:08 amRNSTotal Voting Rights
23rd May 20247:00 amRNSConfirmation of CFO start date
1st May 20241:11 pmRNSTotal Voting Rights
30th Apr 20242:03 pmRNSDirectorate Change
25th Apr 20242:09 pmRNSResult of AGM
25th Apr 20247:00 amRNSQ1 Trading Statement
2nd Apr 20241:49 pmRNSTotal Voting Rights
28th Mar 202412:53 pmRNSDirector/PDMR Shareholding
25th Mar 20244:47 pmRNSDirector/PDMR Shareholding
25th Mar 20242:07 pmRNSAnnual Report 2023 and Notice of AGM 2024
12th Mar 20241:38 pmRNSDirector/PDMR Shareholding
12th Mar 20247:00 amRNSFull Year Results
11th Jan 20246:00 pmRNSDechra Pharmaceuticals
10th Jan 20247:00 amRNSTrading Statement
1st Dec 20234:48 pmRNSBlock listing Interim Review
1st Dec 20234:45 pmRNSTotal Voting Rights
17th Nov 202310:25 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.